12/16
08:07 am
arqt
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis [Yahoo! Finance]
Medium
Report
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis [Yahoo! Finance]
12/16
08:00 am
arqt
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
Medium
Report
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
12/6
04:03 pm
arqt
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
12/6
04:00 pm
arqt
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/3
08:13 am
arqt
Arcutis Announces Promotions on Executive Management Team [Yahoo! Finance]
Low
Report
Arcutis Announces Promotions on Executive Management Team [Yahoo! Finance]
12/3
08:00 am
arqt
Arcutis Announces Promotions on Executive Management Team
Low
Report
Arcutis Announces Promotions on Executive Management Team
11/27
11:17 am
arqt
Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy? [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy? [Yahoo! Finance]
11/20
11:12 am
arqt
Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors [Yahoo! Finance]
11/20
11:12 am
arqt
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average [Yahoo! Finance]
11/19
10:51 am
arqt
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average [Yahoo! Finance]
Medium
Report
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average [Yahoo! Finance]
11/19
08:20 am
arqt
Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors [Yahoo! Finance]
Medium
Report
Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors [Yahoo! Finance]
11/13
08:00 am
arqt
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
Low
Report
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
11/7
08:36 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $18.00 price target on the stock.
Medium
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $18.00 price target on the stock.
11/7
02:31 am
arqt
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ... [Yahoo! Finance]
Medium
Report
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ... [Yahoo! Finance]
11/7
02:26 am
arqt
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript [Seeking Alpha]
11/6
04:00 pm
arqt
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update
11/5
08:04 am
arqt
Earnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2024 Result [Yahoo! Finance]
Medium
Report
Earnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2024 Result [Yahoo! Finance]
11/4
04:00 pm
arqt
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/25
11:48 am
arqt
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release [Yahoo! Finance]
10/24
08:00 am
arqt
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
Low
Report
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
10/23
04:00 pm
arqt
Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference
Low
Report
Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference
10/18
08:25 am
arqt
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older [Yahoo! Finance]
Medium
Report
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older [Yahoo! Finance]
10/18
08:20 am
arqt
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
Medium
Report
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
10/4
04:00 pm
arqt
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/25
01:00 am
arqt
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
Medium
Report
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types